Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-(D)PHE-PRO-BOROHOMOLYS-OH
- Development stage
- Unknown
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
01
Overview
AC-(D)PHE-PRO-BOROHOMOLYS-OH is an experimental small molecule dipeptide containing a boronic acid moiety. Its structure includes an N-acetylated D-phenylalanine, proline, and a borohomolysine residue. The compound acts as a prothrombin inhibitor, suggesting anticoagulant properties by targeting the coagulation cascade at the level of prothrombin (factor II). It has not been approved for clinical use and is primarily studied in preclinical or early research settings[1][2][3].
- Other names
- AC-(D)PHE-PRO-BOROHOMOLYS-OH
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on AC-(D)PHE-PRO-BOROHOMOLYS-OH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AC-(D)PHE-PRO-BOROHOMOLYS-OH.